ArticleBone marrow transplantation2023
EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide.
Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Pre-Transplant Endothelial Activation and Stress Index (EASIX) and Albumin-Modified mEASIX (mEASIX_alb) Predict Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.Medicina (Kaunas, Lithuania) · 2026Article
- Association of EASIX Score with Non-relapse Mortality and Overall Survival in Pediatric Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Stem cell reviews and reports · 2026Article
- Endothelial Activation Stress Index predicts all-cause and cardiovascular mortality in patients with diabetes: A nationwide study.Journal of diabetes investigation · 2025Article
- Endothelial Activation and Stress Index Predicts All-Cause and Cardiovascular Mortality in Hypertensive Individuals: A Nationwide Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Modified EASIX score on day 7 predicts survival and non-relapse mortality in pediatric acute leukemia undergoing haploidentical stem cell transplantation.Frontiers in immunology · 2025Article
- Endothelial Activation and Stress Index (EASIX): A Prognostic Marker for Mortality After Acute Graft-Versus-Host Disease and Endothelial Complications.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Effects of Thalidomide on Endothelial Activation and Stress Index in Children with β-Thalassemia Major.Mediterranean journal of hematology and infectious diseases · 2024Article
- Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores.Hematology. American Society of Hematology. Education Program · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial Activation and Stress Index (EASIX) is a prognostic score reflecting endothelial damage. It can identify cohorts of patients at higher risk of non-relapse mortality (NRM) after allogeneic stem cell transplantation (SCT) from a matched-related or -unrelated donor. No data are available in the setting of haploidentical-SCT with post-transplant cyclophosphamide (PT-Cy). We retrospectively analyzed the role of EASIX score in a cohort of 266 patients receiving Haplo-SCT with PT-Cy at our center. By a decision-tree model, 1-year NRM was 16% vs. 29% and overall survival was 59% vs. 32%, respectively, for patients with a pre-transplant EASIX (EASIX-PRE) <0.8 vs. ≥0.8 (p < 0.001). By multivariable analysis, EASIX-PRE was an independent predictor of NRM (hazard ratio [HR] 2.43, p < 0.001) and overall survival (HR: 1.64, p = 0.011). EASIX-PRE did not predict patients at higher risk of developing acute graft-versus-host disease (GVHD) but was an independent predictor of 1-year NRM (3.2 cutoff, HR 6.61, p = 0.002; <3.2 vs. ≥3.2: 10% vs. 56%, p < 0.001) in patients developing acute GVHD. EASIX score can also represent an important tool to predict mortality in the setting of Haplo-SCT with PT-Cy. It may help to make therapeutic decisions both before the transplant and at the onset of acute GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.